




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Boosting immunity after CoronaVac



Alexandre Schneider/Strings/Getty Images

Published Online
January 21, 2022
[https://doi.org/10.1016/S0140-6736\(22\)00095-2](https://doi.org/10.1016/S0140-6736(22)00095-2)
See [Articles](#) page 521

Recent evidence has shown that COVID-19 immunity and vaccine effectiveness wanes over time.¹ Together with the emergence of the omicron (B.1.1.529) variant with substantial antibody escape,² this resulted in widespread implementation of booster vaccinations to optimise immunity and protection. With increasing availability of vaccines and evidence towards improved immunogenicity of heterologous vaccine regimens,³ knowledge on the immunogenicity of different vaccine combinations and how to best induce booster immunity is of paramount importance to guide vaccination policies. A homologous third dose of CoronaVac (Sinovac) given 8 months after the second dose was shown to be associated with an increase in detectable antibodies,⁴ whereas immunogenicity data for heterologous boosting was unknown.

In *The Lancet*, Sue Costa Clemens and colleagues provide timely results of a randomised trial on the reactogenicity and immunogenicity of a homologous and three different heterologous booster vaccines among individuals who had received two doses of the CoronaVac vaccine.⁵ A total of 1240 individuals from São Paulo and Salvador, Brazil, without history of SARS-CoV-2 infection were randomly assigned to receive a third dose with either CoronaVac, the mRNA vaccine BNT162b2 (Pfizer-BioNTech), or one of the vector vaccines ChAdOx nCov-19 (AstraZeneca), or AD25.COVS-2 (Janssen). Adult study participants were recruited to include two equally sized age groups: younger than 60 years and 61 years and older. 1205 individuals, of whom 729 (60.5%) were women and 814 (67.6%) were White, were available for analysis of primary outcomes, which included reactogenicity and immunogenicity of IgG antibodies and neutralising activity before the boost and 28 days after.⁵

Three serious adverse events possibly related to the vaccine occurred, which resolved completely. Otherwise, all booster doses were well tolerated with commonly observed local and systemic reactions predominantly found after heterologous boosting. Local pain at the injection site was most frequent among recipients of BNT162b2, whereas systemic adverse events predominated among

vector recipients. This safety profile is reassuring and will likely not influence the choice of booster vaccine in clinical practice. Antibody concentrations were remarkably low 6 months after the primary vaccine doses (20.4% [95% CI 12.8–30.1] in adults younger than 60 years and 8.9% [4.2–16.2] in older individuals), and were induced in all study groups by day 28 after boosting. Another recent study from Hong Kong confirmed low median antibody titres in individuals vaccinated with CoronaVac 4 months after primary vaccination.⁶ Although CoronaVac recipients in the present study had the most favourable safety profile, the magnitude of the antibody boost was significantly lower compared with all heterologous regimens. As exemplified for IgG titres, the increase from baseline to 28 days was 12-fold for CoronaVac, 152-fold for BNT162b2, 90-fold for ChAdOx, and 77-fold for AD25.COVS-2. This effect held true for all immunological parameters including neutralising activity, where the booster effect was most pronounced in recipients of BNT162b2, followed by the two vector vaccines where immunogenicity was largely similar. Neutralising capacity towards the delta and omicron variants were well induced after heterologous boosting in more than 90% of individuals. By contrast, only 80% and 35% of individuals after CoronaVac boosting had neutralising activity towards delta and omicron, respectively. Across all vaccines, responses after boosting were lower in the older age group than in the younger group.⁵

Although the COV-BOOST study with different vaccine combinations has shown a similar advantage of mRNA and vector vaccines over adjuvanted protein-based vaccines,⁷ the rapidly spreading omicron variant underscores the need for large cohort studies to determine whether the differences in immunogenicity after booster vaccination observed with age and vaccine regimens will correlate with different susceptibility towards infection or disease. Additionally, with increasing immune escape, there is a need for diagnostic assays adapted to characterise vaccine-induced humoral and cellular immunity towards specific SARS-CoV-2 variants, which should also include determination of meaningful correlates for

protection.^{8,9} Of note, the present study did not assess T-cell immunity, which could inform on the ability to protect from severe disease and which was shown to be markedly induced after heterologous vector or mRNA vaccination in healthy and immunocompromised individuals.^{3,10}

Among approximately 10 billion vaccine doses administered globally, CoronaVac accounts for more than 2 billion doses, making it the world's most frequently used SARS-CoV-2 vaccine.¹¹ It is noteworthy to mention that there are considerable price differences between the SARS-CoV-2 vaccines, which could influence the choice of booster vaccines in low-income and middle-income countries. However, as a result of WHO's endorsement of heterologous vaccine schedules¹² and Costa Clemens' study, we strongly believe that heterologous boosting with mRNA or vector vaccines after primary CoronaVac vaccination should be advised to rapidly regain protective antibody concentrations.

MS has received grant support from Astellas Pharmaceuticals and Biotest to her institution, Saarland University, outside the area of work commented on here, and honoraria for lectures from Biotest and Novartis. SLB has received travel grants and speaker fees from Astellas Pharmaceuticals, Becton Dickinson, Novartis, Pfizer, and Shionogi outside the area of work commented on here, and participated on advisory boards of Pfizer (pertaining to ceftazidime/avibactam) and Shionogi (pertaining to cefiderocol).

*Martina Sester, Sören L Becker
martina.sester@uks.eu

Department of Transplant and Infection Immunology, Saarland University, 66421 Homburg, Germany (MS); Institute of Medical Microbiology and Hygiene, Saarland University, 66421 Homburg, Germany (SLB)

- 1 Chemaïtelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. *N Engl J Med* 2021; **385**: e83.
- 2 Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. *Nature* 2021; published online Dec 23. <https://doi.org/10.1038/s41586-021-04388-0>.
- 3 Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. *Nat Med* 2021; **27**: 1530–35.
- 4 Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. *Lancet Infect Dis* 2021; published online Dec 7. [https://doi.org/10.1016/S1473-3099\(21\)00681-2](https://doi.org/10.1016/S1473-3099(21)00681-2).
- 5 Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. *Lancet* 2022; published online Jan 21; [https://doi.org/10.1016/S0140-6736\(22\)00094-0](https://doi.org/10.1016/S0140-6736(22)00094-0).
- 6 Kwok SL, Cheng SMS, Leung JNS, et al. Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021. *Euro Surveill* 2022; published online Jan 13. <https://doi.org/10.2807/1560-7917>.
- 7 Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *Lancet* 2021; **398**: 2258–76.
- 8 Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly cross-reactive cellular immunity to the SARS-CoV-2 omicron variant. *medRxiv* 2022; published online Jan 3. <https://doi.org/10.1101/2022.01.02.22268634> (preprint).
- 9 Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. *Lancet* 2022; **399**: 234–36.
- 10 Schmidt T, Klemis V, Schub D, et al. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. *Am J Transplant* 2021; **21**: 3990–4002.
- 11 Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations. *Nat Hum Behav* 2021; **5**: 947–53.
- 12 WHO. Interim recommendations for heterologous COVID-19 vaccine schedules. 2021. <https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules> (accessed Jan 14, 2022).

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19



Many initiatives have developed passive immune therapies for COVID-19 patients, including plasma from convalescent donors. Hyperimmune immunoglobulins (hIVIG), extracted from large amounts of COVID-19 convalescent plasma (CCP), as passive immune therapy, needs a longer time span to be developed than CCP, since at least 1000 kg of CCP is required.^{1,2} Moreover, the required logistics and facilities to produce hIVIG make this a more expensive and less accessible alternative to CCP alone. The efficacy and safety of CCP for COVID-19 have been investigated

by several studies, some of which are still ongoing.³ Of these, a large observational study showed that safety of CCP is reasonable.⁴ In December, 2021, the US Food and Drug Administration stated that high-titre anti-SARS-CoV-2 antibody-containing products, such as CCP, should only be used early in the disease course, or in patients with immunosuppressive disease or receiving immunosuppressive treatment.⁵ Randomised controlled trials with high-titre CCP have not shown efficacy in patients hospitalised with COVID-19 to date,^{3,6} with mixed results early in the disease course.^{7,8} This might

Published Online
January 27, 2022
[https://doi.org/10.1016/S0140-6736\(22\)00112-X](https://doi.org/10.1016/S0140-6736(22)00112-X)
See [Articles](#) page 530